-
公开(公告)号：US11325916B1
公开(公告)日：2022-05-10
申请号：US17479248
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Ruichao Shen , Yong He , Xuechao Xing , Matthew C. Rhodes , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14 , A61K31/404
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10961272B2
公开(公告)日：2021-03-30
申请号：US16854334
申请日：2020-04-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
公开(公告)号：US20200331890A1
公开(公告)日：2020-10-22
申请号：US16866778
申请日：2020-05-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20200247839A1
公开(公告)日：2020-08-06
申请号：US16784296
申请日：2020-02-07
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Peng Dai , Guoyou Xu , Bin Wang , Jiang Long , Yat Sun Or
Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, and intermediates of use in said processes.
-
公开(公告)号：US20170334893A1
公开(公告)日：2017-11-23
申请号：US15597417
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Bin Wang , Yong He , Xuechao Xing , Ruichao Shen , Brett Granger , Jing He , Jiang Long , Guoqiang Wang
IPC: C07D413/12 , C07D261/08
CPC classification number: C07D413/12 , A61K31/42 , C07D261/08
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
Patent Agency Ranking
公开(公告)号：US20170304270A1
公开(公告)日：2017-10-26
申请号：US15497268
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Brett Granger , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D261/06 , C07D413/04 , C07D413/12
CPC classification number: A61K31/42 , C07D261/06 , C07D261/08 , C07D413/04 , C07D413/12
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US12018017B2
公开(公告)日：2024-06-25
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
48.发明公开公开(公告)号：US20240132476A1
公开(公告)日：2024-04-25
申请号：US18383949
申请日：2023-10-25
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US11945824B2
公开(公告)日：2024-04-02
申请号：US17503626
申请日：2021-10-18
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Yong He , Kevin McGrath , Ruichao Shen , Adam Szymaniak , Xuechao Xing , In Jong Kim , Guoqiang Wang
IPC: A61K31/706 , A61K31/635 , A61K45/06 , A61P31/14 , A61P35/00 , C07D491/048
CPC classification number: C07D491/048 , A61K45/06 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.-
公开(公告)号：US20230203048A1
公开(公告)日：2023-06-29
申请号：US17983474
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC
Inventor： Guoqiang Wang , Ruichao Shen , Xuechao Xing , Yong He , Matthew C. Rhodes , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.024 seconds)
